This finding was not unexpected, since signaling via other ErbB receptors such as EGFR can compensate for targeted inhibition of ErbB3, suggesting that dual EGFR and ErbB3 blockade may result in improved anti-tumor activity. This evidence concerns the gene EGFR and neoplasm.